Skip to main content

Research News

 

Clinical courses

 

Clinical research courses

  • Exercise restrains Insulin Production, breakthrough research

    When a fruit fly starts walking or flying, its insulin-producing cells are immediately inhibited. This could be one explanation for why exercise promotes health.

    Insulin is an essential hormone for humans and many other living creatures. Its best-known task is to regulate sugar metabolism. How it does this job is well understood. Much less is known about how the activity of insulin-producing cells and consequently the secretion of insulin is controlled.

  • Enzyme that protects against viruses could Fuel Cancer Evolution

    A three-dimensional image of a cancer cell's nucleus obtained by Dr. Faltas and his team shows the APOBEC3G protein (green) inside the nucleus (blue).

    An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells, according to a study led by investigators at Weill Cornell Medicine. The finding suggests that the enzyme may be a potential target for future cancer treatments.

  • iNCOVACC is now available on CoWin

    Bharat Biotech International Limited (BB1L), a global leader in vaccine innovation and developer of vaccines for infectious diseases, today announced that iNCOVACC* (BBV154), is scheduled to be introduced in the country' as a booster dose shortly. Earlier this month, Bharat Biotech received approval from the Central Drugs Standard Control Organization (CDSCO) for the use of heterologous booster doses of iNCOVACC*.

  • BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

    BioNTech SE announced the initiation of a first-in-human Phase 1 study with BNT165b1, the first candidate from the Company’s BNT165 program, to develop a multi-antigen malaria vaccine candidate. BioNTech will initially evaluate a set of mRNA-encoded antigens of the malaria-causing parasite Plasmodium falciparum (P. falciparum) to help select the multi-antigen vaccine candidate to proceed to planned later-stage trials. This first clinical trial (NCT05581641) will evaluate the safety, tolerability and exploratory immunogenicity of the vaccine candidate BNT165b1.

  • Epigenetics breaks into the clinical practice of cancer

    Dr. Manel Esteller and Dr. Verónica Dávalos, researchers at the Josep Carreras Leukaemia Research Institute, describe in a new article the impact of epigenetics on cancer treatment and how it has become a crucial tool to improve early detection, predict disease progression and become a target for new treatments.

  • COVID-19 Booster Increases Durability of Antibody Response

    New research from the University of Virginia School of Medicine speaks to the benefits of a COVID-19 booster.

    The new findings shed light on how mRNA boosters – both Pfizer and Moderna – affect the durability of our antibodies to COVID-19. A booster, the researchers report, made for longer-lasting antibodies for all recipients, even those who have recovered from a COVID-19 infection.

  • Wearable Skin Patch Monitors Hemoglobin in Deep Tissues

    A team of engineers at the University of California San Diego has developed an electronic patch that can monitor biomolecules in deep tissues, including hemoglobin. This gives medical professionals unprecedented access to crucial information that could help spot life-threatening conditions such as malignant tumors, organ dysfunction, cerebral or gut hemorrhages and more.

  • New DNA Analysis Provides First Accurate Tubearculosis Genome

    Researchers have developed a novel genome assembly tool that could spur the development of new treatments for tuberculosis and other bacterial infections.

    The new tool, which has created an improved genome map of one tuberculosis strain, should do likewise for other strains and other types of bacteria, according to researchers whose findings appeared in Nature Communications.

  • Genetic cause of late-onset ataxia found

    A new study published in the New England Journal of Medicine reports the identification of a previously unknown genetic cause of a late-onset cerebellar ataxia, a discovery that will improve diagnosis and open new treatment avenues for this progressive condition.

  • Early sign of osteoarthritis by AI will improve outcome

    Researchers from the University of Jyväskylä and the Central Finland Health Care District have developed an AI based neural network to detect an early knee osteoarthritis from x-ray images. AI was able to match a doctors’ diagnosis in 87% of cases. The result is important because x-rays are the primary diagnostic method for early knee osteoarthritis. An early diagnosis can save the patient from unnecessary examinations, treatments and even knee joint replacement surgery.

Subscribe to Research News